Randomized Trialvery high evidence
Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a).
The New England journal of medicine·November 7, 2026·PMID 43001734
Why it mattersElevated lipoprotein(a) is an independent risk factor for cardiovascular events, and this trial tested whether potent lowering with an antisense oligonucleotide improves outcomes. The neutral result challenges the assumption that reducing lipoprotein(a) translates to clinical benefit, informing risk stratification and therapeutic expectations.

The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled